TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1915134
Drug: Scopolamine i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine i.v. (20 mg)
Study: 1915134
Drug: Placebo i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo i.v. and scopolamine transdermally (0.5 mg)
Study: 1915134
Drug: Transdermally applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermally applied scopolamine (0.5 mg)
Study: 7041931
Drug: Phentolamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine 0.5 mg min‐1 infusion
Study: 2414066
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation (buclizine 6.25 mg, codeine 8 mg, paracetamol 500 mg, with docusate sodium 10 mg)
Study: 2414066
Drug: Combination without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination without docusate (buclizine 6.25 mg, codeine 8 mg, paracetamol 500 mg)
Study: 2414066
Drug: Paracetamol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol alone (500 mg)
Study: 27838646
Drug: Exenatide (17.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (17.4 μg over a 6-hour and 15-minute infusion)
Study: 23980351
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (control group)
Study: 14640996
Drug: Successful treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful treatment of hypercortisolism
Study: 1505304
Drug: HUL/R (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: HUL/R (twice-daily humulin ultralente insulin)
Study: 6388585
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clotrimazole and hydrocortisone (Canesten HC)
Study: 6388585
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clotrimazole and hydrocortisone
Study: 21899733
Drug: Multi-nutrient supplement
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-nutrient supplement
Study: 30771607
Drug: Childbirth preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Childbirth preparation course
Study: 29391277
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi and Physical Therapy
Study: 20515284
Drug: Biomarker testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker testing (e.g., troponin)
Study: 20515284
Drug: Therapeutic intervention
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic intervention (e.g., cardiac catheterization)
Study: 18068058
Drug: Intrapleural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural analgesia with 20 mL of 0.5% bupivacaine every 6 hours for 4 days
Study: 12011120
Drug: Azacitidine (Aza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (Aza C) 75 mg/m(2)/d subcutaneously for 7 days every 28 days
Study: 9803110
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg SR orally immediately post-operatively)
Study: 791332
Drug: Phentolamine (sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (sustained administration)
Study: 791332
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxprenolol and phentolamine
Study: 28921414
Drug: Multimedia diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimedia diabetes education program and nutrition therapy (NT + MDE)
Study: 28921414
Drug: Nutrition therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition therapy only (NT)
Study: 25695189
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with 50 μg dexmedetomidine (RD50)
Study: 25695189
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with 100 μg dexmedetomidine (RD100)
Study: 25695189
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with 150 μg dexmedetomidine (RD150)
Study: 25695189
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with dexmedetomidine (all doses)
Study: 20968112
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg three times a day)
Study: 18321486
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (incremental dose)
Study: 18321486
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin and clomiphene citrate
Study: 17204136
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI) plus general practitioner (GP) supportive care
Study: 11587494
Drug: Naratriptan 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 0 mg
Study: 11587494
Drug: Naratriptan 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 20 mg
Study: 11587494
Drug: Sub-D-optimal design
Normalized name: Water-D sub(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-D-optimal design with Naratriptan 0 mg
Study: 11587494
Drug: Sub-D-optimal design
Normalized name: Water-D sub(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-D-optimal design with Naratriptan 10 mg
Study: 9154396
Drug: Lamisil DermGel
Normalized name: Lamisil
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamisil DermGel (terbinafine 1% emulsion gel) applied once daily for 7 days
Study: 9154396
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied once daily for 7 days
Study: 7957547
Drug: Flumequine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumequine (400 mg, three times daily for 5 days)
Study: 7957547
Drug: Theophylline (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (single i.v. dose)
Study: 3819220
Drug: Grass-pollen immunotherapy
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass-pollen immunotherapy (IT)
Study: 29652278
Drug: Glargine +
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine + human insulin infusion during perioperative period
Study: 29652278
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline + human insulin infusion during perioperative period
Study: 20951370
Drug: Hydrocortisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (30 mg intravenous)
Study: 12410536
Drug: induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: induction chemotherapy arm (n = 86)
Study: 12410536
Drug: all patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all patients (regardless of treatment group)
Study: 7617555
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg x 3)
Study: 2501544
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for premenopausal patients
Study: 2501544
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy for postmenopausal patients
Study: 2501544
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy for receptor-positive patients
Study: 2501544
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for receptor-negative patients
Study: 23262931
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after downregulation (estradiol less than 50 pg/mL) by GnRH antagonist and agonist (arm II)
Study: 23262931
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after downregulation with GnRH agonist (arm IV)
Study: 23262931
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (arm I)
Study: 9667265
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (arm III)
Study: 21878782
Drug: Telephone depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone depression care management + treatment as usual (TAU)
Study: 11387608
Drug: 4F power
Normalized name: 4F-PCC
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4F power injection (Acist)
Study: 9612618
Drug: Adjuvant multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant multimodal treatment including pre- and postoperative chemoradiation, intraoperative radiotherapy (IORT), adjuvant chemotherapy, and regional infusion therapy.
Study: 8070499
Drug: Ibuprofen syrup
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen syrup (7.5 mg/kg)
Study: 8070499
Drug: Acetaminophen syrup
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen syrup (10 mg/kg)
Study: 8070499
Drug: Both ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both ibuprofen and acetaminophen
Study: 21816996
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nonsteroidal anti-inflammatory drugs, orthotics, and home exercise program without dynamic splinting)
Study: 16390354
Drug: mequitazine 10
Normalized name: mequitazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mequitazine 10 mg q.a.m.
Study: 16390354
Drug: dexchlorpheniramine Repetab
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexchlorpheniramine Repetab 6 mg b.i.d.
Study: 16390354
Drug: cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetirizine 10 mg q.a.m.
Study: 14504025
Drug: TREAT (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TREAT (Treatment Research Experiences and Attitudes Task) - a 50-item patient-administered measure of attitudes
Study: 10917410
Drug: Risperidone 0.5
Normalized name: risperidone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 0.5 mg once daily at night, increased to a maximum of 2 mg/day
Study: 2451549
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses (1 mg/kg/day) of corticotherapy
Study: 2451549
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses (0.25 mg/kg/day) of corticotherapy
Study: 28585260
Drug: Optimel Antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimel Antibacterial Manuka Eye Gel (98% Leptospermum species honey) plus conventional therapy, n = 37
Study: 28585260
Drug: Optimel Manuka
Normalized name: GLYCERIN 2 mg in 1 mL OPHTHALMIC GEL [Optimel Manuka Forte Eye Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimel Manuka plus Lubricant Eye Drops (16% Leptospermum species honey) plus conventional therapy, n = 37
Study: 28585260
Drug: Conventional therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy, n = 40
Study: 12938052
Drug: IFN-alpha2b (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2b (low dose) 3 million IU, twice a week for 2 years
Study: 12938052
Drug: IFN-alpha2b (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2b (high dose) 10 million IU, twice a week for 2 years
Study: 9183072
Drug: Concise bonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concise bonding agent
Study: 9183072
Drug: Transbond bonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transbond bonding agent
Study: 16875153
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg twice daily for 4 days
Study: 9017562
Drug: Stage-based telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage-based telephone counseling (3 post-treatment calls)
Study: 6134549
Drug: Opiate analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opiate analgesics
Study: 27596284
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day of pecan nuts
Study: 27596284
Drug: 30 ml/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml/day of olive oil
Study: 25730928
Drug: Enhanced external
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced external counterpulsation (EECP) combined with gaseous carbon dioxide baths and infrared laser therapy
Study: 15813818
Drug: Mepolizumab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (750 mg, two doses, 1 week apart)
Study: 12014211
Drug: Antimicrobial prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial prophylaxis (AP) with orally absorbable antibiotics: 250 mg ciprofloxacin twice a day, 150 mg roxithromycin twice a day, 50 mg fluconazole once a day
Study: 10468294
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alpha-2b (IFN-alpha-2b) intravenous: 20 MIU m(−2), 5 days a week for 4 weeks; subcutaneous: 10 MIU m(−2), 3 times a week for 11 months
Study: 10468294
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alpha-2b (IFN-alpha-2b)
Study: 538418
Drug: Guaiacolic ester
Normalized name: guaiacol
DrugBank: Guaiacol (DB11359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guaiacolic ester of acetylsalicylic acid (ASA-G)
Study: 19717853
Drug: Topical insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin (10 units, 0.1 cc) applied twice daily
Study: 19717853
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 cc saline 0.9% for each 10 cm2 of wound) applied twice daily
Study: 18520804
Drug: Tegafur-uracil (UFT)
Normalized name: tegafur / uracil
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur-uracil (UFT) 200 mg/m2 twice daily from day 1 through 14 plus gemcitabine 900 mg/m2 on days 8 and 15, repeated every 3 or 4 weeks
Study: 18520804
Drug: Tegafur-uracil (UFT)
Normalized name: tegafur / uracil
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur-uracil (UFT) and gemcitabine combination chemotherapy
Study: 8527689
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of talinolol (30 mg)
Study: 8527689
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of talinolol (50 mg)
Study: 137218
Drug: Aminophylline (0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (0.24 g i.v.)
Study: 137218
Drug: Diprophylline (0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprophylline (0.28 g i.v.)
Study: 137218
Drug: Hexoprenaline (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexoprenaline (0.005 mg i.v.)
Study: 137218
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (0.08 mg)
Study: 29451036
Drug: Chondroitin Sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin Sulfate (CS) 800 mg/day
Study: 18433755
Drug: Oral anti-diabetic
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-diabetic agents
Study: 18433755
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (in vitro)
Study: 18433755
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (before and after treatment)
Study: 16988562
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan (3 mg in 1 mL saline)
Study: 16988562
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan (50 mg twice daily for 1 week)
Study: 12636950
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (33 or 133 mg) supplementation from eggs until parturition
Study: 8851608
Drug: Atevirdine alone
Normalized name: Atevirdine
DrugBank: Atevirdine (DB12264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atevirdine alone (treatment B)
Study: 8851608
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of didanosine and atevirdine (treatment C)
Study: 6337198
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution of mixed-grass extract
Study: 6337198
Drug: Histamine solution
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine solution (placebo)
Study: 30269312
Drug: Tafenoquine (TQ)
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tafenoquine (TQ) 400 mg for 3 days
Study: 30269312
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 1500 mg for 3 days then Primaquine (PQ) 15 mg for 14 days
Study: 27410490
Drug: ASP2408 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2408 3.0 mg/kg subcutaneously every 4 weeks
Study: 27410490
Drug: ASP2408 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2408 3.0 mg/kg subcutaneously every 2 weeks
Study: 27410490
Drug: ASP2408 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2408 (various doses)
Study: 20402591
Drug: Azithromycin 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 2.0 g orally as a single dose
Study: 20402591
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G 2.4 million units intramuscularly
Study: 16444089
Drug: Local decongestants
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local decongestants
Study: 16444089
Drug: Local decongestant
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local decongestant followed by nasal dilator
Study: 16444089
Drug: Local decongestant
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local decongestant followed by placebo strip
Study: 11910671
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isoflavone extract
Study: 11910671
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg isoflavone extract
Study: 31096724
Drug: SOC+C+P (chlorpromazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC+C+P (chlorpromazine 12.5 mg BID + promethazine 12.5 mg BID or chlorpromazine 25 mg BID + promethazine 25 mg BID) for 2 weeks
Study: 32615
Drug: Bacampicillin 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 1600 mg twice daily
Study: 32615
Drug: Bacampicillin 800
Normalized name: bacampicillin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 800 mg three times daily
Study: 32615
Drug: Oral ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ampicillin 1000 mg three times daily
Study: 19821718
Drug: CUF2 herbal
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUF2 herbal formula (0.619-g capsule daily for 6 months)
Study: 16423088
Drug: Esomeprazole 2
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 2 x 40 mg, levofloxacin 2 x 500 mg, and amoxicillin 2 x 1 g for 7 days (ELA)
Study: 16423088
Drug: Esomeprazole 2
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 2 x 20 mg, clarithromycin 2 x 500 mg, and amoxicillin 2 x 1 g for 7 days (ECA)
Study: 15801915
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg on-demand treatment
Study: 3874037
Drug: Fluoxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (30 or 60 mg)
Study: 1516463
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 20 mg/kg b.i.d. for 7 days
Study: 1516463
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 20 mg/kg b.i.d. for 10 days
Study: 1516463
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 10 mg/kg b.i.d. for 10 days
Study: 6661468
Drug: Low-dose naloxone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naloxone infusion
Study: 6661468
Drug: High-dose naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naloxone infusion
Study: 22270204
Drug: Dynamiclear formulation
Normalized name: Dynamiclear Oro
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamiclear formulation (copper sulfate pentahydrate and Hypericum perforatum)
Study: 20969660
Drug: DGE (dermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: DGE (dermal gel extra)
Study: 9665673
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 2 IU/m2 for 12 months
Study: 21784603
Drug: Conservative medical
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative medical treatment (Control)